- Conditions
- Dravet Syndrome
- Interventions
- zorevunersen, Sham Comparator
- Drug · Other
- Lead sponsor
- Stoke Therapeutics, Inc
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Dravet Syndrome
- Interventions
- fenfluramine
- Drug
- Lead sponsor
- UCB BIOSCIENCES, Inc.
- Industry
- Eligibility
- 1 Year to 23 Months
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 3
- States / cities
- Memphis, Tennessee • Dallas, Texas • Seattle, Washington
- Conditions
- Dravet Syndrome
- Interventions
- EPX-100 (Clemizole Hydrochloride), Placebos
- Drug
- Lead sponsor
- Epygenix
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Fair Lawn, New Jersey
- Conditions
- Seizures
- Interventions
- Cannabidiol Oral Solution
- Drug
- Lead sponsor
- INSYS Therapeutics Inc
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 11
- States / cities
- San Francisco, California • Miami, Florida • Pensacola, Florida + 8 more
- Conditions
- Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
- Interventions
- Soticlestat
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years to 56 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 19 more
- Conditions
- Dravet Syndrome
- Interventions
- Fenfluramine
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 2 Years and older
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Epilepsies, Myoclonic, Drug Resistant Epilepsy
- Interventions
- Lorcaserin
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 2 Years and older
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 14 more
- Conditions
- CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
- Interventions
- Fenfluramine, Placebo
- Drug
- Lead sponsor
- Zogenix, Inc.
- Industry
- Eligibility
- 1 Year to 35 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Epilepsy, Dravet Syndrome
- Interventions
- GWP42003-P, Placebo Control
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
- Conditions
- Dravet Syndrome
- Interventions
- Clemizole HCl, Placebo
- Drug
- Lead sponsor
- Epygenix
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 27 more
- Conditions
- Epilepsy, Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
- Interventions
- Soticlestat
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 18 more
- Conditions
- Dravet Syndrome
- Interventions
- ZX008 (Fenfluramine Hydrochloride)
- Drug
- Lead sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
- Industry
- Eligibility
- 2 Years to 35 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- San Francisco, California • Aurora, Colorado
- Conditions
- Cyclin-Dependent Kinase-Like 5 Deficiency Disorder
- Interventions
- No intervention; observational
- Other
- Lead sponsor
- Loulou Foundation
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Aurora, Colorado • Norcross, Georgia + 6 more
- Conditions
- Dravet Syndrome
- Interventions
- Fenfluramine treatment (Fintepla), Hypercapnia Challenge using the device (RespirAct)
- Drug · Device
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Dravet Syndrome, Seizure Disorder
- Interventions
- ZX008 (Fenfluramine Hydrochloride), Matching Placebo
- Drug
- Lead sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Tucson, Arizona • San Diego, California + 15 more
- Conditions
- Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS)
- Interventions
- CBD: GT4 Transdermal Delivery System
- Drug
- Lead sponsor
- Alexander Rotenberg
- Other
- Eligibility
- 2 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Dravet Syndrome, Epileptic Encephalopathies Associated With SCN1A Mutations
- Interventions
- Stiripentol
- Drug
- Lead sponsor
- Cook Children's Health Care System
- Other
- Eligibility
- 6 Months to 18 Years
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Dravet Syndrome
- Interventions
- Clobazam, Placebo
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 1 Year to 16 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Orlando, Florida • Rochester, Minnesota + 4 more
- Conditions
- Dravet Syndrome
- Interventions
- ION337
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- Ann Arbor, Michigan • Rochester, Minnesota • Durham, North Carolina + 2 more
- Conditions
- Dravet Syndrome
- Interventions
- Stiripentol
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 6 Months and older
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Dravet Syndrome
- Interventions
- Verapamil
- Drug
- Lead sponsor
- Gillette Children's Specialty Healthcare
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Rochester, Minnesota • Saint Paul, Minnesota + 1 more
- Conditions
- Dravet Syndrome
- Interventions
- stiripentol
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 11 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
- Interventions
- Specimen sample
- Diagnostic Test
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Dravet Syndrome
- Interventions
- Retrospective study
- Other
- Lead sponsor
- Biocodex
- Industry
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota